// App-Quantinova.ai

OP0103 : DOES GENDER, AGE OR SUBPOPULATION INFLUENCE THE MAINTENANCE OF CLINICAL REMISSION IN AXIAL SPONDYLOARTHRITIS FOLLOWING CERTOLIZUMAB PEGOL DOSE REDUCTION?

Researchers

Presenter

  • R. B. M. Landew

Principal Investigators

  • D. Van der Heijde

  • M. Dougados

  • X. Baraliakos

  • F. Van den Bosch

  • K. Gaffney

  • L. Bauer

  • B. Hoepken

  • N. De Peyrecave

  • K. Thomas

  • L. S. Gensler

Medical Centers

  • Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

  • Zuyderland Medical Center, Heerlen, Netherlands

  • Leiden University Medical Centre, Leiden, Netherlands

  • Paris Descartes University, Cochin Hospital, Paris, France

  • Ruhr-University Bochum, Herne, Germany

  • Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

  • Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom.

  • UCB Pharma, Monheim am Rhein, Germany

  • UCB Pharma, Brussels, Belgium

  • University of California–San Francisco - California - United States of America

Locations

  • Netherlands

  • France

  • Germany

  • Belgium

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT02505542

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved